Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — H1 2019 Earnings Presentation

48 slides from Aspen Pharmacare's earnings presentation, Mar 8, 2019

  1. Slide 1: 2019 Interim Results

    2019 Interim Results For the six months ended 31st December 2018

  2. Slide 2: Financial Review

    Financial Review

  3. Slide 3: Disclaimer

    DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S.

  4. Slide 4: Disclosure Notes

    DISCLOSURE NOTES • Results separately disclose discontinued operations arising from the pending and completed disposals of the Nutritionals business and a non-core pharmaceutical products portfolio in the Asia Pacific region • Adoption of new IFRS 9 (Financial instruments) and 15 (Revenue from contr

  5. Slide 5: Financial Highlights

    FINANCIAL HIGHLIGHTS CONTINUING OPERATIONS % Change vs PY R’million H1 2019 Reported* CER** Net revenue 19 673 1% 0% Gross profit 10 236 2% 2% Gross profit margin 52.0% 0.5ppt 1.4ppt EBITDA 5 534 -3% -1% EBITDA margin 28.1% -1.2ppt -0.3ppt Net Financing Costs 902 20% 17% Tax 631 -8% -6% Normalised e

  6. Slide 6: EBITDA Margin

    EBITDA MARGIN CONTINUING OPERATIONS Contribution to change in Normalised EBITDA Margin -0.3% -0.9% 29.3% 2.3% -1.1% -0.9% -1.4% 28.4% -0.2% 0.1% -0.5% 28.1% -1.4% -0.9% H1 2018 FX impact H1 2018 Normalised Steriles Other Selling & Distribution Administrative Depreciation Net other H1 2019 Normalised

  7. Slide 7: Currency Impact

    CURRENCY IMPACT CONTINUING OPERATIONS Average FX Rates Contribution to Contribution to H1 2018 FY 2018 H1 2019 • ZAR contribution to ZAR revenue Normalised EBITDA − Revenue: 19% EUR 29% 8% 15.77 15.33 16.34 − Normalised EBITDA: 17% AUD 11% 19% 10.45 9.96 10.27 • Positive translation impact of relati

  8. Slide 8: Reconciliation of CER NHEPS

    RECONCILIATION OF CER NHEPS CONTINUING OPERATIONS Cents H1 2019 H1 2018 % change Basic earnings per share (EPS) 628.9 728. 7 -14% Profit on sale of property, plant and equipment 0.1 0.2 Impairment of PPE 1.6 2.3 Impairment of intangible assets 45.9 30.1 Reversal of impairment of PPE (0.1) - Loss on

  9. Slide 9: PPE Capital Expenditure

    PPE CAPITAL EXPENDITURE Planned Capex spend – Anaesthetics PPE Capex - R'million (approx R4.5 billion) 5% 3 500 21% 3 000 H2 2019 2 500 1 800 2 600 2 000 2 145 74% 1 500 PE NDB BO 1 484 1 500 1 000 H1 2019 1 200 1 168 • Construction of buildings nearing completion 500 • Equipment installation has co

  10. Slide 10: Working Capital

    WORKING CAPITAL CONTINUING OPERATIONS Working Capital – R’million 19 103 • Inventory increased by stock builds 664 − Transfer of Mono-Embolex API and finished dose 245 manufacture to NDB -3 − Heparin safety stock 1 086 17 111 − Serialisation − Brexit • Settlement of long-standing accruals for restru

  11. Slide 11: Nutritionals Divestment

    NUTRITIONALS DIVESTMENT • Agreement reached with Lactalis in September 2018 • Both parties committed to closure on 31 May 2019 − Approval for Lactalis investment by New Zealand Overseas Investment Office the only outstanding external condition precedent − Remaining conditions precedent within the co

  12. Slide 12: Cash Flow

    CASH FLOW CONTINUING OPERATIONS • H1 2019 operating cash flows constrained by working capital investment − Operating cash flow per share of 317 cents − Conversion rate of 47% • Strong H2 cash flows expected − FY 2019 operating cash flow conversion rate between 90% and 100% − Net proceeds from Nutrit

  13. Slide 13: Borrowings

    BORROWINGS 53 507 6 Movement in Net Borrowings - R’million 4 943 -409 47 749 1 498 46 780 969 -1 711 1 431 South Africa - ZAR 23% International - EUR 69% Net Borrowings FX impact Net Borrowings Cashflow from Distribution to Capex Proceeds from Acquisition Other Net Borrowings at 30 June 2018 at 30 J

  14. Slide 14: Borrowings

    BORROWINGS Analysis of R53.5 billion net borrowings H1 2019 Key Indicators H1 2019 H1 2018 53.5 pro formaa Net borrowings 43.1 Net borrowings R43.1bn R53.5bn R43.1bn Normalised net funding costs R735m R902m R753m Gearing 43% 51% 50% 9.9 Cash 8.5 Net Debt/EBITDAd 3.7xb 4.4x 3.6x Interest cover ratiod

  15. Slide 15: Business Overview

    Business Overview

  16. Slide 16: Current Status & Priorities

    CURRENT STATUS & PRIORITIES • Period since 2014 has transformed Aspen • Now a global multi-national specialty pharma company − Portfolio of niche brands including steriles and biochem − 70 established operations in 56 countries  Predominantly across Emerging Markets − Complex production capabilitie

  17. Slide 17: Increase Focus

    INCREASE FOCUS • Nutritionals disposal allows full focus on pharma − Aside from New Zealand Overseas Investment Office  All external conditions fulfilled, agreed closure on 31 May 2019 − Material value creation − Insufficient critical mass for global penetration − Nutritionals ~ 4% of EBIT • Non-co

  18. Slide 18: Performance Review

    Performance Review

  19. Slide 19: Group Revenue

    GROUP REVENUE CONTINUING OPERATIONS Commercial Pharma Revenue R’million H1 2019 H1 2018 % change H1 2018 (CER)* % change R16.7bn Commercial Pharma** 16 687 16 323 2% 16 434 2% Emerging Markets Regional Brands 8 886 8 639 3% 8 610 3% +5% growth Sterile Focus Brands 7 801 7 684 2% 7 824 0% R7.3bn R9.4

  20. Slide 20: Commercial Pharma - Regional Brands

    COMMERCIAL PHARMA - REGIONAL BRANDS CONTINUING OPERATIONS Regional Brands Revenue H1 2018 R’million H1 2019 % change R8.9bn (CER) Middle East Africa 4 308 4 062 6% Asia Pacific 2 328 2 261 3% Developed Markets +0% growth Rest of World 1 200 1 317 -9% Latin America 1 050 970 8% R3.1bn R5.8bn 35% 65%

  21. Slide 21: Commercial Pharma - Regional Brands: Middle East Africa

    COMMERCIAL PHARMA - REGIONAL BRANDS MIDDLE EAST AFRICA Regional Brands MEA Revenue R4.3 billion • Prescription segment key growth driver +6% growth − OTC sales contribution between 25% – 30% − Maintaining growth off high base 8% In 77 therapeutic classes – contributing 80% of total 9% South Africa m

  22. Slide 22: Commercial Pharma - Regional Brands: Asia Pacific

    COMMERCIAL PHARMA - REGIONAL BRANDS ASIA PACIFIC • Australasia and Japan > 85% of sales Regional Brands Asia Pacific Revenue − 1% growth in Japan R2.3 billion +3% growth Australasia 11% • Revenue contribution >70% − 6% growth 72% Australia: Overall Rep Performance Rankings • OTC sales contribution ±

  23. Slide 23: Commercial Pharma - Sterile Focus Brands

    COMMERCIAL PHARMA – STERILE FOCUS BRANDS Sterile Focus Brands Revenue R’million H1 2019 H1 2018 % change R7.8bn (CER) Anaesthetics 4 412 4 450 -1% Thrombosis 3 389 3 374 0% Emerging Markets Total 7 801 7 824 0% +5% growth • Sterile pricing resilient R3,4bn R3.1bn R5.8bn − In spite of global pharma p

  24. Slide 24: Sterile Focus Brands - Thrombosis

    STERILE FOCUS BRANDS – THROMBOSIS H1 2018 R’million H1 2019 % change (CER) Europe CIS 2 735 2 853 -4% Thrombosis Revenue Rest of World 654 521 26% R3.4bn Total 3 389 3 374 0% Emerging Markets Europe CIS ↓ 4% +7% growth • More than 50% of decline attributable to Russia CIS − Reduction of Arixtra stoc

  25. Slide 25: Sterile Focus Brands - Thrombosis

    STERILE FOCUS BRANDS – THROMBOSIS Europe Thrombosis Annual Revenue (excluding Russia CIS) EU Thrombosis market EUR’m • Biosimilars affecting originator 293 − 10% market share of Germany, UK and Italy 286 288 • Aspen market share resilient but not making inroads into €’million 198 197 200 above marke

  26. Slide 26: Sterile Focus Brands - Anaesthetics

    STERILE FOCUS BRANDS – ANAESTHETICS Anaesthetics Revenue H1 2018 R4.4bn R’million H1 2019 % change Emerging (CER) Markets Asia Pacific 2 318 2 360 -2% +4% growth Developed Europe 1 131 1 166 -3% Rest of World 963 924 4% R2.4bn R2.0bn Total 4 412 4 450 -1% 54% 46% Developed Markets • Year-on-year glo

  27. Slide 27: Looking Forward

    Looking Forward

  28. Slide 28: USA Pipeline - Aspen's Highest Pipeline Potential

    USA PIPELINE – ASPEN’S HIGHEST PIPELINE POTENTIAL Women’s Health assets • Aspen has reached a broad promotion/revenue share agreement with a partner − Partner has clear commitment to and capability in therapeutic area in the USA − Partner targeting peak sales of greater than USD 500 million  Once a

  29. Slide 29: Build on Our Strengths & Drive Organic Growth

    BUILD ON OUR STRENGTHS & DRIVE ORGANIC GROWTH Superior capabilities in Emerging Markets • Organic growth driver • Commercial Pharma Emerging Markets growth of 5% for the period Optimise our complex manufacturing capabilities • Continue to work towards completion of major capex projects for Anaesthet

  30. Slide 30: De-lever the Balance Sheet

    DE-LEVER THE BALANCE SHEET Create headroom for new opportunities • Proceeds from Nutritionals disposal • Proceeds from Asia Pacific portfolio divestment • Potential inflows from strategic reviews • Full focus on organic growth drivers • Medium term target of leverage ratio < 3.0 − Deleveraging accel

  31. Slide 31: Portfolio Management Strategy

    PORTFOLIO MANAGEMENT STRATEGY Maximise portfolio Build portfolio Reshape portfolio returns Drivers of portfolio Aspen Portfolio strategy Sales & Supply Acquire Develop Collaborate Manufacturing Revitalise Collaborate Divest Marketing Chain Patients needs Proactively seek Leverage Strategic Leverage

  32. Slide 32: Summary

    SUMMARY • To transform Aspen from a regional generics business to a global specialty business at this rate/scale − Without any equity injection − Will come with growing pains • Created significant value from acquisitions made • Demonstration of ability to both de-lever and drive organic growth Austr

  33. Slide 33: Summary | Continued

    SUMMARY | CONTINUED • Anaesthetics portfolio was a stretch but strategically critical − Finally over material deferred acquisition payments • Intention is to act as we have historically − Repay acquisition debt through portfolio optimisation and organic cash flows − Partner/divest where others have

  34. Slide 34: Appendices

    APPENDICES Appendix 1: Appendix 8: Abridged statement of comprehensive income Commercial Pharma revenue by segment Appendix 2: Appendix 9: Reconciliation of reported NHEPS Net funding costs Appendix 3: Appendix 10: Group statement of financial position Working Capital reconciliation Appendix 4: Appe

  35. Slide 35: Appendix 1: Abridged Statement of Comprehensive Income

    APPENDIX 1: ABRIDGED STATEMENT OF COMPREHENSIVE INCOME R’million H1 2019 H1 2018 % change Net revenue 19 673 19 509 1% Cost of sales (9 437) (9 460) Gross profit 10 236 10 049 2% Gross profit margin 52.0% 51.5% Operating expenses (5 083) (4 801) Net other operating expenses (733) (547) Depreciation

  36. Slide 36: Appendix 2: Reconciliation of Reported NHEPS

    APPENDIX 2: RECONCILIATION OF REPORTED NHEPS INCLUDING DISCONTINUED OPERATIONS Cents H1 2019 H1 2018 % change Basic earnings per share (EPS) 643.4 798.6 -19% Profit on sale of property, plant and equipment 0.1 0.2 Net impairment of property, plant and equipment 1.6 2.5 Impairment of intangible asset

  37. Slide 37: Appendix 3: Group Statement of Financial Position

    APPENDIX 3: GROUP STATEMENT OF FINANCIAL POSITION R'million H1 2019 H1 2018* R‘million H1 2019 H1 2018* TOTAL ASSETS EQUITY AND LIABILIITIES Non-current assets 89 475 86 351 Shareholders equity 52 290 43 934 Intangible assets 70 297 67 326 Non-current liabilities 60 370 37 813 Property, plant and eq

  38. Slide 38: Appendix 4: IFRS Restatements

    APPENDIX 4: IFRS RESTATEMENTS Implementation of IFRS 9 Financial Instruments (Expected loss provisioning) and IFRS 15 (Revenue from contracts with customers) became effective for Aspen in the 2019 financial year. Aspen assessed and applied the new standards and presents the December 2018 interim res

  39. Slide 39: Appendix 5: Extract from Group Statement of Cash Flows

    APPENDIX 5: EXTRACT FROM GROUP STATEMENT OF CASH FLOWS CONTINUING OPERATIONS R‘million H1 2019 H1 2018 % change Cash operating profit 5 852 6 092 -4% Changes in working capital (2 253) (1 470) 53% Cash generated from operations 3 599 4 622 -22% Net finance costs paid (765) (607) 26% Tax paid (1 123)

  40. Slide 40: Appendix 6: Abridged Statement of Normalised Comprehensive Income

    APPENDIX 6: ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME CONTINUING OPERATIONS R’million H1 2019 H1 2018 % change H1 2018 (CER) % change Net revenue 19 673 19 509 1% 19 743 0% Cost of sales (9 437) (9 460) 0% (9 748) Gross profit 10 236 10 049 2% 9 995 2% Gross profit margin 52.0% 51.5% 50.

  41. Slide 41: Appendix 7: Group Revenue by Region

    APPENDIX 7: GROUP REVENUE BY REGION CONTINUING OPERATIONS H1 2018 R’million H1 2019 H1 2018* % Change % Change (CER)** Developed Europe 6 210 6 347 -2% 6 589 -6% Sub-Saharan Africa 4 322 4 393 -2% 4 424 -2% Asia Pacific 5 464 5 167 6% 5 251 4% Latin America 1 551 1 522 2% 1 387 12% Developing Europe

  42. Slide 42: Appendix 8: Commercial Pharma Revenue by Segment

    APPENDIX 8: COMMERCIAL PHARMA REVENUE BY SEGMENT CONTINUING OPERATIONS R’million H1 2019 H1 2018* % change H1 2018 (CER)** % change Regional Brands 8 886 8 639 3% 8 610 3% Regional Brands 6 834 6 469 6% 6 428 6% High Potency & Cytotoxics 2 052 2 170 -5% 2 182 -6% Sterile Focus Brands 7 801 7 684 2%

  43. Slide 43: Appendix 9: Net Funding Costs

    APPENDIX 9: NET FUNDING COSTS CONTINUING OPERATIONS R’million H1 2019 H1 2018 Higher borrowings Net interest paid (684) (586) Reduced deferred Foreign exchange (losses)/gains (41) 50 consideration Notional interest on financial instruments (177) (217) payable Normalised net funding costs (902) (753)

  44. Slide 44: Appendix 10: Working Capital Reconciliation

    APPENDIX 10: WORKING CAPITAL RECONCILIATION CONTINUING OPERATIONS R’million H1 2019 FY 2018 H1 2018 Net Working capital - Reported 19 103 18 157 17 793 Less IFRS 9 and 15 restatement - (521) (502) Net working capital - Restated 19 103 17 636 17 291 Nutritionals - held for sale - (899) (699) FX impac

  45. Slide 45: Appendix 11: Borrowings

    APPENDIX 11: BORROWINGS Net Borrowings: R53.5 billion Blended NACQ interest rates for borrowings as at 31 December 2018 Asia Pacific Blended interest rates 5% ZAR 8.8% South Africa 19% AUD 4.2% EUR 2.0% International 76% 45

  46. Slide 46: Appendix 12: Gross Debt Maturity Profile

    APPENDIX 12: GROSS DEBT MATURITY PROFILE Debt Maturity Profile – R’million 25 887 16 479 6 600 5 968 ZAR 4 103 EUR 3 547 AUD 800 0-1 years 1-3 years 3+ years The above debt maturity profile does not factor in unamortised capital raising fees (ZAR 151m at 31 December 2018) which are deducted from bor

  47. Slide 47: Appendix 13: Capital Allocation Model

    APPENDIX 13: CAPITAL ALLOCATION MODEL Manufacturing capability & capacity Re-investment into business for sustainable growth Internal development of Cash Flow Generation existing IP Value Creation Emerging Markets South Africa - ZARStrategic M&A Investment in strategically 23% aligned opportunities

  48. Slide 48: Appendix 14: Institutional Investors

    APPENDIX 14: INSTITUTIONAL INVESTORS 9.6% South Africa 1.2% 1.3% 1.4% 1.5% USA 2.0% Singapore Switzerland 14.5% Scotland Saudi Arabia UK 68.5% Other As at 31 December 2018 48

Aspen Pharmacare Holdings — H1 2019 Earnings Presentation on 6ix